Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company has a collaboration agreement with Navigo Proteins GmbH for the advancement of affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorMedical
Phone781-250-0111
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$194.03 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Repligen (NASDAQ:RGEN) Frequently Asked Questions
What is Repligen's stock symbol?
Repligen trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen's earnings last quarter?
Repligen Co. (NASDAQ:RGEN) posted its earnings results on Thursday, February, 21st. The biotechnology company reported $0.21 EPS for the quarter, hitting the consensus estimate of $0.21. The biotechnology company had revenue of $51.90 million for the quarter, compared to analyst estimates of $50.27 million. Repligen had a return on equity of 5.51% and a net margin of 8.56%. Repligen's revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period last year, the company earned $0.20 earnings per share. View Repligen's Earnings History.
When is Repligen's next earnings date?
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY19 earnings guidance on Thursday, February, 21st. The company provided earnings per share guidance of $0.81-0.86 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.85. The company issued revenue guidance of $218-225 million, compared to the consensus revenue estimate of $217.22 million.Repligen also updated its FY 2019 guidance to $0.81-0.86 EPS.
What price target have analysts set for RGEN?
7 brokerages have issued twelve-month price objectives for Repligen's stock. Their forecasts range from $55.00 to $70.00. On average, they expect Repligen's share price to reach $60.25 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price. View Analyst Price Targets for Repligen.
What is the consensus analysts' recommendation for Repligen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen.
Has Repligen been receiving favorable news coverage?
Press coverage about RGEN stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Repligen earned a news impact score of 1.1 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Repligen's key competitors?
Some companies that are related to Repligen include Cochlear (COH), Steris (STE), Genmab A/S (GNMSF), Aurora Cannabis (ACB), Alnylam Pharmaceuticals (ALNY), BioMerieux (BMXMF), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Sarepta Therapeutics (SRPT), Sartorius (SRT), Qiagen (QGEN), Henry Schein (HSIC), H. Lundbeck A/S- (HLUYY), Molina Healthcare (MOH) and bluebird bio (BLUE).
What other stocks do shareholders of Repligen own?
Who are Repligen's key executives?
Repligen's management team includes the folowing people:
- Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 55)
- Mr. Jon K. Snodgres, CFO & Sec. (Age 53)
- Mr. Steve Curran, VP of Global Operations
- Ms. Sondra S. Newman, Sr. Director of Investor Relations
- Mr. Stephen Tingley, VP of Sales
Who are Repligen's major shareholders?
Repligen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.73%), Conestoga Capital Advisors LLC (3.68%), Macquarie Group Ltd. (2.43%), Dimensional Fund Advisors LP (2.31%), Lord Abbett & CO. LLC (1.67%) and Ranger Investment Management L.P. (1.41%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.
Which major investors are selling Repligen stock?
RGEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Conestoga Capital Advisors LLC, Macquarie Group Ltd., Dimensional Fund Advisors LP, Boston Advisors LLC, Kornitzer Capital Management Inc. KS, New York State Common Retirement Fund and Summit Creek Advisors LLC. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.
Which major investors are buying Repligen stock?
RGEN stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Ardevora Asset Management LLP, Norges Bank, Millennium Management LLC, Prudential Financial Inc., WINTON GROUP Ltd, Westpac Banking Corp and Two Sigma Investments LP. View Insider Buying and Selling for Repligen.
How do I buy shares of Repligen?
Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen's stock price today?
One share of RGEN stock can currently be purchased for approximately $59.41.
How big of a company is Repligen?
Repligen has a market capitalization of $2.61 billion and generates $194.03 million in revenue each year. The biotechnology company earns $16.62 million in net income (profit) each year or $0.73 on an earnings per share basis.
What is Repligen's official website?
How can I contact Repligen?
Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]
MarketBeat Community Rating for Repligen (NASDAQ RGEN)
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
